Decode.
We mine massive multi-dimensional translatome datasets to identify cell-specific nuances in the genetic
code unique to different cell types. Malignant versus non-malignant. Immune cells versus liver cells.
Design.
We incorporate these signatures into the mRNA design, creating selective therapies that activate only in specific cell types.
Deliver.
We control the programmed mRNA’s journey using proprietary, antibody-decorated LNPs. These advanced delivery vehicles evade default accumulation in the liver and reach target sites, such as tumors, spleen and bone marrow.
